Olupot-Olupot Peter, Paasi George, Katairo Thomas, Alunyo Jimmy Patrick, Nakiyemba Alice, Ocen Gilbert Gilibrays, Pande Stephen, Alaroker Florance, Okiror William, Ocen Emmaluel, Oula Alex, Okalebo Charles Benard, Paul Ongodia, Amorut Denis, Tukwasibwe Stephen, Ndidde Susan Nabadda, Sewanyana Isaac, Nsobya Samuel L
Mbale Clinical Research Institute (MCRI), P.O. Box 1966, Mbale, Uganda.
Faculty of Health Sciences, Busitema University, P.O. Box 1460, Mbale, Uganda.
Malar J. 2025 Jun 13;24(1):190. doi: 10.1186/s12936-025-05439-x.
In Uganda, antimalarial resistance in Plasmodium falciparum poses serious public health and treatment challenges. Globally, recent data have highlighted the roles of following genes in malaria resistance: Plasmodium falciparum dihydrofolate reductase (Pfdhfr), Plasmodium falciparum dihydropteroate synthetase (Pfdhps), Plasmodium falciparum chloroquine resistance transporter (Pfcrt), Plasmodium falciparum multidrug resistance gene 1 (Pfmdr1), and Plasmodium falciparum K13 propeller domain (Pfk13). This study investigated the prevalence and characteristics of P. falciparum molecular markers linked to antimalarial resistance in Northern, Northeastern, and Eastern Uganda.
This cross-sectional study collected 200 dried blood samples from children (2 months to 12 years) in Northern, Eastern, and Northeastern Uganda. Samples were from malaria-positive cases confirmed by rapid diagnostic tests and microscopy. Genomic DNA was extracted from these samples and analysed using Molecular Inversion Probes to detect Plasmodium falciparum genetic mutations. The sequencing was performed on the Illumina MiSeq platform, and raw data was organized and analysed with MIPTools software.
The study sequenced over 50% of the samples at each site as follows: Apac 87.7% (43/49), Moroto 68.0% (34/50), Soroti 65.0% (13/20) and Mbale 53.1% (43/81). The Pfk13 A675V and C469Y mutations varied from 0 to 23.3% and 8.3-14.3%, in four sites, with consistently low prevalence in Apac. The Pfdhfr N51I and S108N mutations were fixed in all districts, while C59R was fixed in Moroto and nearing fixation (92-97%) in other regions. The emerging I164L mutation ranged from 1 to 10% in all sites. The Pfdhps A437G and K540E mutations were fixed in Soroti, with 3-5% wild-type prevalence in other sites. The A581G mutation showed 2.3% mixed genotypes in Mbale only. The Pfcrt K76T was predominantly wild type, except for 5% mutants in Mbale and Moroto. The pfmdr1 N86Y were wild type across all districts, except for 15% mixed genotypes in Soroti.
This study reveal rising partial artemisinin resistance and widespread antifolate resistance surpassing WHO thresholds in Northern, Northeastern, and Eastern Uganda. Emerging super-resistant parasites pose a serious threat to malaria control, necessitating urgent enhanced surveillance and alternative treatment strategies.
在乌干达,恶性疟原虫的抗疟耐药性给公共卫生和治疗带来了严峻挑战。在全球范围内,近期数据凸显了以下基因在疟疾耐药性中的作用:恶性疟原虫二氢叶酸还原酶(Pfdhfr)、恶性疟原虫二氢蝶酸合酶(Pfdhps)、恶性疟原虫氯喹耐药转运蛋白(Pfcrt)、恶性疟原虫多药耐药基因1(Pfmdr1)以及恶性疟原虫K13螺旋桨结构域(Pfk13)。本研究调查了乌干达北部、东北部和东部与抗疟耐药性相关的恶性疟原虫分子标记的流行情况及特征。
这项横断面研究从乌干达北部、东部和东北部的儿童(2个月至12岁)中收集了200份干血样。样本来自经快速诊断检测和显微镜检查确诊的疟疾阳性病例。从这些样本中提取基因组DNA,并使用分子倒置探针进行分析,以检测恶性疟原虫的基因突变。测序在Illumina MiSeq平台上进行,原始数据用MIPTools软件进行整理和分析。
该研究对每个地点超过50%的样本进行了测序,具体如下:阿帕克87.7%(43/49)、莫罗托68.0%(34/50)、索罗蒂65.0%(13/20)以及姆巴莱53.1%(43/81)。Pfk13 A675V和C469Y突变在四个地点的发生率在0至23.3%和8.3 - 14.3%之间,在阿帕克一直保持低发生率。Pfdhfr N51I和S108N突变在所有地区均为固定型,而C59R突变在莫罗托为固定型,在其他地区接近固定型(92 - 97%)。新出现的I164L突变在所有地点的发生率在1%至10%之间。Pfdhps A437G和K540E突变在索罗蒂为固定型,在其他地点野生型发生率为3%至5%。A581G突变仅在姆巴莱显示出2.3%的混合基因型。Pfcrt K76T主要为野生型,姆巴莱和莫罗托有5%的突变型。pfmdr1 N'86Y在所有地区均为野生型,索罗蒂有15%的混合基因型除外。
本研究表明,在乌干达北部、东北部和东部,青蒿素部分耐药性呈上升趋势,广泛的抗叶酸耐药性超过了世界卫生组织的阈值。新出现的超级耐药寄生虫对疟疾控制构成严重威胁,因此迫切需要加强监测并制定替代治疗策略。